Preprogen is a privately held, women’s health company with the first-and-only, non-invasive, at-home gynecologic cancer cell collection screening kit, PadKit™. Preprogen aims to empower women at risk for endometrial cancer and other health issues and their physicians by giving them peace of mind knowing that Preprogen products provide a fast and non-invasive modern approach to cancer cell screening.
There is currently no standard or routine screening test to detect endometrial cancer. Preprogen’s PadKit is designed to detect endometrial cancer and other gynecologic cancers, known cancer biomarkers (e.g., BRCA1, BRCA2), vaginal infections, infectious diseases, including STDs, fetal conditions, and other women’s health issues to empower women’s health prescribed by and under the comprehensive care of a physician.
“Our goal is to reduce deaths from endometrial cancer…
it’s as simple as that.”
— Dr. Shalom Hirschman, Chief Scientific Officer & Medical Director and
Eli Goldberger, Founder & Chief Executive Officer
Preprogen’s novel cell science technology is proven to collect whole, intact cells from a woman’s gynecologic tract in the comfort of her home for fast lab screening.
Empower women’s health through early gynecologic cancer screening
To provide women and their doctors with a trusted, at-home screening tool to detect gynecologic cancers and other health issues early when treatment may be curative.
“We are on a mission to stop cancer from killing the people we love.”
— Eli Goldberger, Founder & Chief Executive Officer
“Preprogen’s cell science technology brings a much-needed innovation to detecting gynecologic cancers and protecting
— Margaret Blaetz, Chief Compliance Officer